Scientists have discovered a unique human antibody in the blood of a volunteer who had received an experimental vaccine made from weakened malaria parasites (PfSPZ Vaccine-Sanaria). The volunteer developed a unique malaria-targeting antibody named CI43. This antibody had the ability to protect mice from infection with the deadliest malaria parasite Plasmodium falciparum. Furthermore, the volunteer carrying this unique antibody, was later exposed to infectious malaria-carrying mosquitoes under carefully controlled conditions, and did not become infected.
The research findings provide the basis for future testing in humans to determine if the antibody can provide short-term protection against malaria, and also aid in a future long-lasting vaccine design. Currently, there is no highly effective, long-lasting vaccine to prevent malaria, a mosquito-spread disease that causes some 430,000 deaths each year, primarily among young children in sub-Saharan Africa.
Investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, led this research with colleagues at the Fred Hutchinson Cancer Research Center in Seattle. Additional collaborators on the study included scientists at the Johns Hopkins Bloomberg School of Public Health in Baltimore, the Seattle Biomedical Research Institute and Sanaria Inc., Rockville, Maryland.
Capra Science Antibodies looks forward to following the development of their research.
Source:
Neville K Kisalu, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nature Medicine, 2018; DOI: 10.1038/nm.4512
https://www.niaid.nih.gov/
The research findings provide the basis for future testing in humans to determine if the antibody can provide short-term protection against malaria, and also aid in a future long-lasting vaccine design. Currently, there is no highly effective, long-lasting vaccine to prevent malaria, a mosquito-spread disease that causes some 430,000 deaths each year, primarily among young children in sub-Saharan Africa.
Investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, led this research with colleagues at the Fred Hutchinson Cancer Research Center in Seattle. Additional collaborators on the study included scientists at the Johns Hopkins Bloomberg School of Public Health in Baltimore, the Seattle Biomedical Research Institute and Sanaria Inc., Rockville, Maryland.
Capra Science Antibodies looks forward to following the development of their research.
Source:
Neville K Kisalu, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nature Medicine, 2018; DOI: 10.1038/nm.4512
https://www.niaid.nih.gov/